CpG ODN–mediated BM graft rejection is dependent upon functional donor BM APCs
| Experiment no. . | Donor . | Donor wild-type BM add-back . | Recipient . | CpG . | Engraftment rate . | Donor chimerism, mean % ± 1 SEM . |
|---|---|---|---|---|---|---|
| 1 | B6 | None | BALB/c | No | 10/10 | 91 ± 1 |
| 1 | B6 | None | BALB/c | Yes | 8/9 | 67 ± 13† |
| 1 | B6 MHCII−/− | None | BALB/c | No | 9/9 | 84 ± 7 |
| 1 | B6 MHCII−/− | None | BALB/c | Yes | 9/9 | 70 ± 11 |
| 1 | B6 MHCII−/− | CD19+CD11b+ | BALB/c | No | 10/10 | 94 ± 2 |
| 1 | B6 MHCII−/− | CD19+CD11b+ | BALB/c | Yes | 5/9* | 49 ± 16* |
| 2 | BALB/c TLR9−/− | None | B6 | No | 9/10 | 57 ± 12 |
| 2 | BALB/c TLR9−/− | None | B6 | Yes | 7/9 | 64 ± 13 |
| 2 | BALB/c TLR9−/− | CD11b+ | B6 | No | 7/8 | 75 ± 12 |
| 2 | BALB/c TLR9−/− | CD11b+ | B6 | Yes | 2/7* | 27 ± 18* |
| 2 | BALB/c TLR9−/− | CD19+ | B6 | No | 9/10 | 67 ± 9 |
| 2 | BALB/c TLR9−/− | CD19+ | B6 | Yes | 8/9 | 62 ± 10 |
| Experiment no. . | Donor . | Donor wild-type BM add-back . | Recipient . | CpG . | Engraftment rate . | Donor chimerism, mean % ± 1 SEM . |
|---|---|---|---|---|---|---|
| 1 | B6 | None | BALB/c | No | 10/10 | 91 ± 1 |
| 1 | B6 | None | BALB/c | Yes | 8/9 | 67 ± 13† |
| 1 | B6 MHCII−/− | None | BALB/c | No | 9/9 | 84 ± 7 |
| 1 | B6 MHCII−/− | None | BALB/c | Yes | 9/9 | 70 ± 11 |
| 1 | B6 MHCII−/− | CD19+CD11b+ | BALB/c | No | 10/10 | 94 ± 2 |
| 1 | B6 MHCII−/− | CD19+CD11b+ | BALB/c | Yes | 5/9* | 49 ± 16* |
| 2 | BALB/c TLR9−/− | None | B6 | No | 9/10 | 57 ± 12 |
| 2 | BALB/c TLR9−/− | None | B6 | Yes | 7/9 | 64 ± 13 |
| 2 | BALB/c TLR9−/− | CD11b+ | B6 | No | 7/8 | 75 ± 12 |
| 2 | BALB/c TLR9−/− | CD11b+ | B6 | Yes | 2/7* | 27 ± 18* |
| 2 | BALB/c TLR9−/− | CD19+ | B6 | No | 9/10 | 67 ± 9 |
| 2 | BALB/c TLR9−/− | CD19+ | B6 | Yes | 8/9 | 62 ± 10 |
Experiment 1: BALB/c recipient mice were irradiated (5.0 Gy TBI) on d−1 and infused with 10 × 106 TCD donor BM cells from either B6 wild-type or B6 MHCII−/− mice on d0. Cohorts of mice received B6 wild-type CD19+CD11b+ BM cells (10 × 106) added to the B6 MHCII−/− donor BM inoculum. Experiment 2: B6 recipient mice were irradiated (6.0 Gy TBI) on d−1 and infused with 10 × 106 BALB/c TLR9−/− TCD donor BM cells on d0. Cohorts of mice received BALB/c wild-type CD11b+ or CD19+ BM cells (5 × 106) added to the BALB/c TLR9−/− donor BM inoculum. CpG ODNs were given intraperitoneally on d0 and d7 (100 μg/dose). n = 10 per group. Engraftment was assessed at 40 days after BMT by PBL phenotyping. Engraftment rate indicates proportion of mice that had a minimum of 5% donor chimerism.
P < .05 compared with relevant untreated control.
P = .06 compared with relevant untreated control.